Proposed $200 Million At-The-Market Equity Offering Program

On July 19, 2026, Ascentage Pharma Group International announced plans for an at-the-market (ATM) equity offering program to raise up to $200 million through the sale of American Depositary Shares (ADSs) on Nasdaq. The company filed a Form F-3 registration statement with the SEC and entered into a sales agreement with Citigroup, Deutsche Bank, and BTIG as sales agents. The ATM program allows the company to sell ADSs incrementally at prevailing market prices over time, providing flexibility to raise capital when market conditions are favorable. Proceeds are intended to fund commercialization of Olverembatinib and Lisaftoclax, ongoing clinical trials, working capital, and general corporate purposes. The company has applied for waivers from certain Hong Kong Listing Rules requirements and notes that no sales will occur until these waivers are granted. The program utilizes an existing general mandate from shareholders and does not require additional shareholder approval.